[1] Pose E, Abigueli T, Reverter E. A notable proportion of liver trans plant with alcoholrelated cirrhosis can be delisted because of clinical improvements[J]J Hepatol, 2021,75(2):275-283. [2] Aravinthan A D,Barbas A S,Doylr A C.Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study[J].Transpl Int,2017,30(11):1140-1149. [3] Glard J M,Dodge J L,Terrault N A.Superior wait-list outcomes in patients with alcohol-associated liver disease compared with other indications for liver transplantation[J].Liver Transpl,2019,25(9):1310-1320. [4] 中华医学会肝病学分会. 肝硬化腹水诊疗指南(2023年版)[J]. 中华肝 脏 病 杂 志 , 2023, 31(8): 813-826. [5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南(2018更新版)中华肝脏病杂志,2018,26(3):188-194. [6] Hofer B S, Simbrunner B, Hart L, et al. Hepatic recompensation according to Baveno Ⅶ criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis[J]. Liver Int,2023,43(10):2220-2231. [7] 张培.失代偿期肝炎肝硬化再代偿临床特征及相关影响因素研究[D].成都:电子科技大学,2024. [8] Hui V W, Wong G L, Wong V W, et al. Baveno Ⅶ criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis[J].JHEP Rep, 2023,5(9):100814. [9] Zhang Y, Liu X, Li S, et al. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: a retrospective study based on Baveno Ⅶ criteria[J].Hepatol Commun, 2024, 8(1):e0355. [10] Wang Q, Zhao H, Deng Y, et al. Validation of Baveno Ⅶ criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol,2022, 77(6): 1564-1572. [11] He Z, Wang B, Wu X, et al. Recompensation in treatment-naïve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding[J].Hepatol Int, 2023,17(6):1368-1377. [12] Premkumar M, Dhiman R K, Duseja A, et al. Recompensation of chronic hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: prospective cohort study from a hepatitis C virus elimination program[J]. Gastroenterology,2024,167(7):1429-1445. [13] Semmler G, Lens S, Hidalgo Á, et al. Incidence and clinical significance of recompensation after HCV cure[J]. Clin Gastroenterol Hepatol,2025;23(13):2488-2498.e8. [14] 许丹青, 木唤, 张映媛, 等.丙型肝炎肝硬化失代偿患者再代偿的影响因素分析[J]. 临床肝胆病杂志, 2025, 41(2): 269-276. [15] Hofer B S, Burghart L, Halibasic E, et al. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis[J]. Aliment Pharmacol Ther,2024,59(8):962-972. [16] Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis[J].Drug Alcohol Rev, 2010,29(4):437-445. [17] Hofer B S,Simbrunner B,Hartil L, et al.Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis [J].Clin Gastroenterol Hepatol,2023,21(9):2308-2317.e7. [18] Shen Z, Li Y M, Yu C H, et al. Risk factors for alcohol-related liver injury in the island population of China: a population-based case-control study [J].World J Gastroenterol, 2008,14(14):2255-2261. [19] 王洪岩,李 鑫,徐有青.酒精性肝病发病机制研究进展[J].实用肝脏病杂志,2014,(1):5-8. [20] 陈洪锁,孟宪梅.酒精性肝病分子机制的研究进展[J].包头医学院学报,2018,34(8):127-129. [21] Arroyo V, Angel P, Moreu R, et al.The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis.[J]. J Hepatol,2021,74(3):670-685. [22] Costa D, Simbrunner B, Jachs M, et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality[J]. J Hepatol,2021,74(4):819-828. [23] Tonon M, Gagliiardi R, Pompili E, et al.Validation and expansion of Baveno Ⅶ recompensation criteria in patients with cirrhosis and curable liver disease[J].J Hepatol,2025 ,83(4):888-898 [24] Wen S, Ruan J, Shen J,et al. Development and validation of a nomogram to predict recompensation in HBV-related cirrhosis with ascites as the single first decompensating event[J].Scand J Gastroenterol,2023,58(8):915-922. [25] Chang M L, Cheng J S, Chen R N, et al. Hepatitis flares are associated with better outcomes than no flare in patients with decompensated cirrhosis and chronic hepatitis B virus infection.[J].Clin Gastroenterol Hepatol,2020,18(9):2064.e2-2072.e2. [26] 谢飞.开发和验证预测乙型肝炎肝硬化失代偿患者再代偿的列线图模型[D].南昌:南昌大学,2024. [27] Reiberger T, Puspok A, Schoder M, et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth Ⅲ)[J]. Wien Klin Wochenschr, 2017, 129(Suppl 3): 135-158. [28] Benmssaud A, Freeman S C, Roccarina D, et al. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis[J]. Cochrane Database Syst Rev, 2020,1:CD013123. |